If you're in Australia and weighing up obesity treatment right now, there's a question that comes up constantly and almost never gets answered properly: do you start Mounjaro today, or hold out for retatrutide? The retatrutide vs Mounjaro decision looks like a comparison of two drugs, but it's really a comparison of two timelines — one available on a private script this month, one that Eli Lilly doesn't plan to even file with regulators until 2027. Here's how to think about it without the hype.

Retatrutide vs Mounjaro: what's actually on the table

Mounjaro is tirzepatide, a dual agonist — it works on two receptors, GLP-1 and GIP. It's TGA-approved and available in Australia now, and its pivotal weight-management trial programme (SURMOUNT-1) reported average total body weight reduction in the low-to-mid 20% range at the top dose over 72 weeks, depending on which analysis you read.

Retatrutide adds a third target: glucagon. GLP-1 plus GIP plus glucagon receptor agonism — hence "triple agonist". In the phase 3 TRIUMPH-1 trial, retatrutide produced up to around 28.3% average body weight loss at the 12mg dose over 80 weeks, with 45.3% of participants losing 30% or more of their starting weight.

So on the numbers, retatrutide is ahead. But retatrutide is investigational and not TGA-approved, it cannot be prescribed here outside a clinical trial, and Lilly's stated plan is to begin regulatory filings from 2027. Read that as approval decisions landing at the earliest in the late 2020s, with Australian availability and any PBS conversation trailing behind that. More on the local sequence in our Australia guide.

The real question isn't "which is better" — it's "what does waiting cost"

Comparing 28.3% to ~21% makes the choice look obvious. It isn't, because the two numbers aren't available on the same day.

If retatrutide reaches Australian pharmacies in, say, 2029, then choosing to "wait" means several years at your current weight. For someone with obesity plus sleep apnoea, knee osteoarthritis, prediabetes or elevated cardiovascular risk, those years aren't neutral — they're years of accumulated exposure. Waiting is not a pause button; it's a decision with its own risk profile.

Also worth noting: the headline percentages are trial averages from different studies, different populations and different durations. They were never designed to be compared directly. A properly powered head-to-head trial of retatrutide against tirzepatide is the only thing that would settle it, and the published evidence base doesn't contain one yet. Anyone quoting you a precise "retatrutide is X% better than Mounjaro" figure is doing arithmetic the data doesn't support. We unpack the trial design detail in clinical trials.

Starting now doesn't lock you out of later

The other misconception is that beginning tirzepatide somehow forfeits your place in the queue for retatrutide. It doesn't. Incretin therapy has been stepwise from the beginning — people moved from liraglutide to semaglutide, and from semaglutide to tirzepatide, as better options arrived. If retatrutide is eventually approved in Australia, switching will be a clinical conversation with your prescriber, not a penalty for having started earlier.

There's a practical Australian wrinkle, though. Access here has been genuinely uneven — supply of GLP-1 medicines has fluctuated, and PBS subsidy for these drugs remains narrow, so most weight-management prescriptions are private and out-of-pocket. If cost is what's driving the "I'll just wait" instinct, be honest that retatrutide is very unlikely to arrive cheaper. New patented biologics don't launch at bargain prices, and PBS listing is a separate, slower fight after registration.

What a genuinely useful comparison looks like

Instead of ranking the molecules, ask four questions with your GP:

  • What am I treating? If it's type 2 diabetes plus weight, tirzepatide already has an approved diabetes indication and a subsidy pathway that retatrutide won't have for years.
  • What's my tolerance history? Both drugs share the GLP-1 side effect profile — nausea, vomiting, constipation, dose-escalation discomfort. Retatrutide's glucagon component also drew attention for heart-rate increases in trials. See safety.
  • What's my time horizon? If you're managing a condition that worsens year on year, waiting is expensive in ways the scales don't show.
  • Am I eligible for a trial? Participation is currently the only legitimate route to retatrutide in Australia, and eligibility criteria are strict.

If you want the mechanism explained without the marketing, start with what is retatrutide.

Where this leaves Australians in 2026

Right now the honest summary is: Mounjaro is a real option today with real evidence behind it; retatrutide is a stronger candidate on paper that is still years from an Australian pharmacy shelf, and whose final approved dosing, label and price are all unknown. Treating the second as a reason not to act on the first is a bet on a timeline nobody controls.

The best move for most people is to make a decision with a clinician based on what exists now, and stay informed about what's coming. Join the free updates list and we'll email you when retatrutide reaches a milestone that actually changes Australian access — a filing, a TGA decision, a PBS submission — rather than every press cycle.

FAQ

Is retatrutide better than Mounjaro?

In separate trials retatrutide produced a higher average weight loss (up to about 28.3% at 12mg over 80 weeks) than tirzepatide's pivotal weight-management results, but the studies weren't designed for direct comparison and no head-to-head trial has been published. Retatrutide is also still investigational and unapproved in Australia.

Should I wait for retatrutide instead of starting Mounjaro?

For most people, no — Eli Lilly doesn't plan to begin regulatory filings until 2027, so Australian availability is likely several years away. Waiting means years of untreated obesity risk, and starting one therapy doesn't prevent you switching later if retatrutide is approved.

Can I get retatrutide in Australia in 2026?

Not through a pharmacy. Retatrutide has no TGA approval, so the only legitimate access route in Australia is enrolment in a clinical trial, subject to strict eligibility criteria.

Will retatrutide be cheaper than Mounjaro in Australia?

Unlikely at launch. New patented biologics typically enter the market at premium prices, and PBS subsidy is a separate process that happens after TGA registration — so early access would almost certainly be private and out-of-pocket.

Sources

Disclaimer: This article is general information only and is not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA for use in Australia. Always speak with your GP or a qualified health professional before starting, stopping or changing any treatment. retatrutide.net.au is an independent Australian information site and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company.